First Ascent Biomedical offers a drug prediction platform that utilizes causal machine learning and therapy-resistant cell technologies to create personalized cancer treatment plans based on individual tumor vulnerabilities. This approach provides advanced cancer patients with data-driven options after standard therapies have failed, significantly improving treatment planning efficiency with a turnaround time of approximately 10 days.
Funding
$6.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
ICSEVDFounders
Product
Problem
Advanced cancer patients who have exhausted standard therapies often lack effective treatment options due to the unique and complex nature of their individual tumors. Traditional treatment approaches may fail to address specific vulnerabilities present in these tumors, leading to limited success and poor patient outcomes.
Solution
First Ascent Biomedical offers a drug prediction platform, DxPP, that leverages causal machine learning and therapy-resistant cell technologies to identify personalized cancer treatment plans based on individual tumor vulnerabilities. The platform utilizes a patient's live tumor tissue sample to grow therapy-resistant cells, which are then screened against hundreds of FDA-approved drugs. AI/ML algorithms analyze the drug screening results in conjunction with DNA/RNA sequencing data to map tumor weaknesses and prioritize therapeutic solutions. The platform delivers a custom treatment recommendation report, complete with supporting rationale, to the patient's oncologist within approximately 10 days, providing data-driven options for patients after standard therapies have failed.
Target Audience
The primary users are oncologists treating advanced cancer patients who have exhausted standard therapies, as well as pharmaceutical companies seeking to accelerate drug development and identify biomarkers.
Features
- _Ex Vivo_ Drug Response Identification & Validation Engine
- xDRIVE platform integrates functional drug testing, DNA/RNA sequencing, and AI-guided tumor weakness mapping.
- Drug screening tests hundreds of FDA-approved drugs on therapy-resistant cells grown from the patient's own tumor tissue.
- AI/ML analysis identifies tumor weaknesses and prioritizes therapeutic solutions tailored to the patient's tumor vulnerabilities.
- The platform supports single drug and drug combination testing.
- Provides real-time pharmacological and multi-omics preclinical data.
- Generates explainable multi-omics biomarkers.
- Facilitates pre-enrollment screening for oncology clinical trials.